Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Ozempic Sales Soar 56% in Q3. But Is Eli Lilly a Better Stock to Buy Than Novo Nordisk?

TheMotleyFool

0 0

Ozempic Sales Soar 56% in Q3. But Is Eli Lilly a Better Stock to Buy Than Novo Nordisk?: https://g.foolcdn.com/editorial/images/753454/ozempic.jpg

Is the fervor over Ozempic just a passing fad? It doesn't appear to be the case after Novo Nordisk (NYSE: NVO) announced its results for the first nine months of 2023 on Thursday morning.

Ozempic sales soared in the third quarter. Unsurprisingly, investors reacted positively to Novo Nordisk's results, with the big drugmaker's shares jumping nearly 4% in early trading.

However, Eli Lilly (NYSE: LLY) reported its Q3 results on Thursday as well, and its share price jumped close to 7%. Is Lilly a better stock to buy than Novo Nordisk?

Source Fool.com

Like: 0

LLY

Share